Clinical Trial Update: A Single-Center Open-Label Study of 1064 nm for Nonablative Skin Rejuvenation [NA]

View source ↗

Summary

A single-center open-label study evaluating 1064 nm nonablative skin rejuvenation has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Photoaging
• Skin Pigment

Drugs mentioned

• 1064 nm nonablative skin rejuvenation treatment

Snippet

Sponsor: Cutera Inc. | Conditions: Skin Pigment, Photoaging | NA | Status: COMPLETED | Results posted: 2023-09-06